Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Illumina, Inc.
The company expects the major commercial collaboration and geographical roll-out will lead to increased adoption of Agendia’s breast cancer diagnostics.
The annual J.P. Morgan Healthcare Conference includes presentations from major medtech companies describing their experience in 2021 and expectations for 2022. Here are some highlights from the in vitro diagnostics companies that presented on the first two days of the meeting.
Qiagen’s doubled-down focus on PCR technologies in late 2019 proved to be fortuitous, but future growth will come from many other drivers, says CFO Roland Sackers.
How can stakeholders capitalize on this moment of acute public awareness of diagnostics to improve adoption of tests and screening in the long term? At a recent roundtable event, the CEOs of Roche Diagnostics, GE Healthcare, Labcorp and Synlab, among others, gave their thoughts on how the system must change.
Research, Analytical Equipment & Supplies
- PCR & Amplification Tools
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Nanotechnology, Chips, etc.
Drug Discovery Tools
- Other Names / Subsidiaries
- GenoLogics Life Sciences Software
- GRAIL Inc.
- Verinata Health
- Illumina Ventures